Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Conditions
Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Endometrial Neoplasms · Ovarian Neoplasms · Pancreatic Neoplasms · Biliary Tract Neoplasms
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
USC Norris Cancer Hospital, Los Angeles, California, United States
Chao Family Comprehensive Cancer Ctr., Orange, California, United States
Yale-New Haven Hospital, New Haven, Connecticut, United States
AdventHealth Orlando, Orlando, Florida, United States
Florida Cancer Specialists, Sarasota, Florida, United States
Indiana Univ Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
Community Health Network, Indianapolis, Indiana, United States
Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
NYU Langone Health- Long Island, Mineola, New York, United States
NYU Langone, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Novant Health Cancer Institute - Elizabeth, Charlotte, North Carolina, United States
Novant Health Cancer Institute - Forsyth, Winston-Salem, North Carolina, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
Vanderbilt Univeristy School of Medicine, Nashville, Tennessee, United States
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
START Mountain Region, West Valley City, Utah, United States
Inova Health System IRB, Fairfax, Virginia, United States
USO-Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States
Royal North Shore Hospital, St Leonards, New South Wales, Australia
St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
Cancer Research SA, Adelaide, South Australia, Australia
Peninsula and Southeast Oncology, Frankston, Victoria, Australia
Linear Clinical Research, Nedlands, Western Australia, Australia
Cross Cancer Institute, Edmonton, Alberta, Canada
Princess Margaret Hospital (Ontario), Toronto, Ontario, Canada
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, Aquitaine, France
Centre Leon Berard, Lyon, Auvergne-Rhône-Alpes, France
Institut du Cancer de Montpellier - Val d'aurelle, Montpellier, France
Institut Claudius Regaud - IUCT Oncopole, Toulouse, France
Gustave Roussy, Villejuif, France
Aichi Cancer Center Hospital, Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Kanazawa University Hospital, Kanazawa, Ishikawa-ken, Japan
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Wakayama Medical University Hospital, Wakayama, Japan
National Cancer Center, Goyang-si, Gyeonggi-do, South Korea
The Catholic University of Korea, St. Vincent's Hospital, Suwon, Gyeonggi-do, South Korea
Chonnam National University Hwasun Hospital, Hwasun-gun, Jeonranamdo, South Korea
Seoul National University Hospital, Seoul, Korea, South Korea
Asan Medical Center, Seoul, Korea, South Korea
Study leads
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company